|
Article Excerpt
FRANKLIN LAKES, N.J. -- ReGen Biologics, Inc. (OTC: RGBI) an orthopedic products company that develops, manufactures and markets innovative products for human tissue repair in the U.S. and abroad, announced today that five (5) year follow-up data from its feasibility study regarding the company's patented Collagen Meniscus Implant (CMI) has been published as the lead article in the May 2005 issue of the peer-reviewed journal Arthroscopy.
Commenting on the publication, Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics, stated, "This article in Arthroscopy represents the first peer reviewed, published overview of the clinical benefits of the CMI." Dr. Bisbee continued, "With an estimated 9 million partial...
|
|
More articles from Business Wire
RIVERBED Licenses Industry-Leading WAN Acceleration Technology to HP f..., May 17, 2005
'Ocean Cargo Container Security' Is Top Concern of Global Supply Chain..., May 17, 2005
Amerix Announces Results From Ouro Roxo South Drilling., May 17, 2005
The TJX Companies, Inc. Reports First Quarter Fiscal 2006 Results., May 17, 2005
EXACT Sciences Shows Link Between DNA Preservation and Improved Non-In..., May 17, 2005
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
